BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Watts KD, Seshadri R, Sullivan C, McColley SA. Increased prevalence of risk factors for morbidity and mortality in the US Hispanic CF population. Pediatr Pulmonol 2009;44:594-601. [PMID: 19437506 DOI: 10.1002/ppul.21037] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Watts KD. Healthcare Inequalities in Paediatric Respiratory Diseases. Paediatric Respiratory Reviews 2012;13:57-62. [DOI: 10.1016/j.prrv.2011.05.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
2 Schechter MS. Nongenetic influences on cystic fibrosis outcomes. Curr Opin Pulm Med 2011;17:448-54. [PMID: 21897254 DOI: 10.1097/MCP.0b013e32834ba899] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kerem E, Cohen-cymberknoh M. Disparities in Cystic Fibrosis Care and Outcome. Chest 2016;149:298-300. [DOI: 10.1016/j.chest.2015.08.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
4 Oud L. Critical illness among adults with cystic fibrosis in Texas, 2004-2013: Patterns of ICU utilization, characteristics, and outcomes. PLoS One 2017;12:e0186770. [PMID: 29065161 DOI: 10.1371/journal.pone.0186770] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
5 Kern-Goldberger AS, Hill-Ricciuti AC, Zhou JJ, Savant AP, Rugg L, Dozor AJ, Welter J, Saiman L, Quittell LM. Perceptions of safety monitoring in CF clinical studies and potential impact on future study participation. J Cyst Fibros 2019;18:530-5. [PMID: 31151855 DOI: 10.1016/j.jcf.2019.05.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Bustamante AE, Fernández LT, Rivas LC, Mercado-Longoria R. Disparities in cystic fibrosis survival in Mexico: Impact of socioeconomic status. Pediatr Pulmonol 2021;56:1566-72. [PMID: 33656284 DOI: 10.1002/ppul.25351] [Reference Citation Analysis]
7 McGarry ME, Neuhaus JM, Nielson DW, Burchard E, Ly NP. Pulmonary function disparities exist and persist in Hispanic patients with cystic fibrosis: A longitudinal analysis. Pediatr Pulmonol 2017;52:1550-7. [PMID: 29082671 DOI: 10.1002/ppul.23884] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
8 McShane PJ, Naureckas ET, Strek ME. Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture. Chest 2012;142:159-67. [PMID: 22267679 DOI: 10.1378/chest.11-1024] [Cited by in Crossref: 64] [Cited by in F6Publishing: 55] [Article Influence: 6.4] [Reference Citation Analysis]
9 Mcgarry ME, Gibb ER, Oates GR, Schechter MS. Left Behind: The Potential Impact of CFTR Modulators on Racial and Ethnic Disparities in Cystic Fibrosis. Paediatric Respiratory Reviews 2021. [DOI: 10.1016/j.prrv.2021.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kopp BT, Nicholson L, Paul G, Tobias J, Ramanathan C, Hayes D Jr. The Geographic Impact on Hospitalization in Patients with Cystic Fibrosis. J Pediatr 2016;170:246-52.e1-4. [PMID: 26690850 DOI: 10.1016/j.jpeds.2015.11.012] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
11 Parker-McGill K, Nugent M, Bersie R, Hoffman G, Rock M, Baker M, Farrell PM, Simpson P, Levy H. Changing incidence of cystic fibrosis in Wisconsin, USA. Pediatr Pulmonol 2015;50:1065-72. [PMID: 26258862 DOI: 10.1002/ppul.23265] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
12 Dongarwar D, Garcia BY, Miller K, Salihu HM. Assessment of hospitalization rates, factors associated with hospitalization and in-patient mortality in pediatric patients with cystic fibrosis. J Natl Med Assoc 2021:S0027-9684(21)00190-5. [PMID: 34479733 DOI: 10.1016/j.jnma.2021.08.038] [Reference Citation Analysis]
13 Buu MC, Sanders LM, Mayo JA, Milla CE, Wise PH. Assessing Differences in Mortality Rates and Risk Factors Between Hispanic and Non-Hispanic Patients With Cystic Fibrosis in California. Chest 2016;149:380-9. [PMID: 26086984 DOI: 10.1378/chest.14-2189] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
14 Kern AS, Watts KD, Rychlik K, Mccolley SA. Disparities in Parental Health Literacy at a Pediatric Cystic Fibrosis Center. Pediatric Allergy, Immunology, and Pulmonology 2015;28:55-9. [DOI: 10.1089/ped.2014.0396] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
15 McGarry ME, Williams WA 2nd, McColley SA. The demographics of adverse outcomes in cystic fibrosis. Pediatr Pulmonol 2019;54 Suppl 3:S74-83. [PMID: 31715087 DOI: 10.1002/ppul.24434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
16 McGarry ME, Huang CY, Nielson DW, Ly NP. Early acquisition and conversion of Pseudomonas aeruginosa in Hispanic youth with cystic fibrosis in the United States. J Cyst Fibros 2021;20:424-31. [PMID: 33162303 DOI: 10.1016/j.jcf.2020.10.002] [Reference Citation Analysis]
17 Oates GR, Schechter MS. Socioeconomic determinants of respiratory health in patients with cystic fibrosis: implications for treatment strategies. Expert Rev Respir Med 2022;:1-14. [PMID: 35705523 DOI: 10.1080/17476348.2022.2090928] [Reference Citation Analysis]
18 Salvatore D, Buzzetti R, Baldo E, Furnari ML, Lucidi V, Manunza D, Marinelli I, Messore B, Neri AS, Raia V. An overview of international literature from cystic fibrosis registries. Part 4: update 2011. J Cyst Fibros. 2012;11:480-493. [PMID: 22884375 DOI: 10.1016/j.jcf.2012.07.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
19 Betz CL. Approaches to transition in other chronic illnesses and conditions. Pediatr Clin North Am 2010;57:983-96. [PMID: 20883887 DOI: 10.1016/j.pcl.2010.07.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
20 Watts KD, Schechter MS. Origins of outcome disparities in pediatric respiratory disease. Pediatr Ann 2010;39:793-8. [PMID: 21162488 DOI: 10.3928/00904481-20101116-10] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
21 Oates GR, Schechter MS. Socioeconomic status and health outcomes: cystic fibrosis as a model. Expert Review of Respiratory Medicine 2016;10:967-77. [DOI: 10.1080/17476348.2016.1196140] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
22 Wagener JS, Woo MS, Pasta DJ, Konstan MW, Morgan WJ. Liver Involvement in the Hispanic Population of North America With Cystic Fibrosis. Journal of Pediatric Gastroenterology & Nutrition 2014;59:476-9. [DOI: 10.1097/mpg.0000000000000448] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
23 McGarry ME, Neuhaus JM, Nielson DW, Ly NP. Regional variations in longitudinal pulmonary function: A comparison of Hispanic and non-Hispanic subjects with cystic fibrosis in the United States. Pediatr Pulmonol 2019;54:1382-90. [PMID: 31144477 DOI: 10.1002/ppul.24377] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
24 Kay DM, Langfelder-schwind E, Decelie-germana J, Sharp JK, Maloney B, Tavakoli NP, Saavedra-matiz CA, Krein LM, Caggana M, Kier C; the New York State Cystic Fibrosis Newborn Screening Consortium. Utility of a very high IRT/No mutation referral category in cystic fibrosis newborn screening: Very High IRT in Newborn CF Screening. Pediatr Pulmonol 2015;50:771-80. [DOI: 10.1002/ppul.23222] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
25 Watts KD, Layne B, Harris A, McColley SA. Hispanic Infants with cystic fibrosis show low CFTR mutation detection rates in the Illinois newborn screening program. J Genet Couns 2012;21:671-5. [PMID: 22311127 DOI: 10.1007/s10897-012-9481-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
26 McColley SA, Ren CL, Schechter MS, Regelmann WE, Pasta DJ, Konstan MW; Epidemiologic Study of Cystic Fibrosis. Risk factors for onset of persistent respiratory symptoms in children with cystic fibrosis. Pediatr Pulmonol 2012;47:966-72. [PMID: 22359344 DOI: 10.1002/ppul.22519] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
27 Mccolley SA, Schechter MS, Morgan WJ, Pasta DJ, Craib ML, Konstan MW. Risk factors for mortality before age 18 years in cystic fibrosis. Pediatr Pulmonol 2017;52:909-15. [DOI: 10.1002/ppul.23715] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 9.4] [Reference Citation Analysis]
28 Kopp BT, Nicholson L, Paul G, Tobias J, Ramanathan C, Hayes D. Geographic variations in cystic fibrosis: An analysis of the U.S. CF Foundation Registry: Geographic Variations in CF. Pediatr Pulmonol 2015;50:754-62. [DOI: 10.1002/ppul.23185] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
29 McGarry ME, McColley SA. Minorities Are Underrepresented in Clinical Trials of Pharmaceutical Agents for Cystic Fibrosis. Ann Am Thorac Soc 2016;13:1721-5. [PMID: 27410177 DOI: 10.1513/AnnalsATS.201603-192BC] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]